Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
49.00
+3.30 (7.22%)
At close: Nov 22, 2024, 4:00 PM
49.51
+0.51 (1.04%)
After-hours: Nov 22, 2024, 6:19 PM EST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 373 employees as of December 31, 2023. The number of employees decreased by 20 or -5.09% compared to the previous year.
Employees
373
Change (1Y)
-20
Growth (1Y)
-5.09%
Revenue / Employee
$2,539,826
Profits / Employee
$1,052,190
Market Cap
6.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Waystar Holding | 1,400 |
Inspire Medical Systems | 1,011 |
Ionis Pharmaceuticals | 927 |
Lantheus Holdings | 834 |
Blueprint Medicines | 655 |
Cytokinetics | 423 |
HALO News
- 1 day ago - Halozyme withdraws $2.1 bln buyout offer for Evotec - Reuters
- 1 day ago - Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions - PRNewsWire
- 5 days ago - Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - Market Watch
- 5 days ago - Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec - PRNewsWire
- 8 days ago - Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - Benzinga
- 9 days ago - Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction - PRNewsWire
- 9 days ago - Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - Reuters
- 18 days ago - Halozyme: Looking For More Growth Following Record Q3 Earnings - Seeking Alpha